Your browser doesn't support javascript.
loading
Impact of thoracic tumor radiotherapy on survival in non-small-cell lung cancer with malignant pleural effusion treated with targeted therapy: Propensity score matching study.
Li, Qingsong; Hu, Cheng; Su, Shengfa; Ma, Zhu; Geng, Yichao; Hu, Yinxiang; Jin, Haijie; Li, Huiqin; Lu, Bing.
Affiliation
  • Li Q; Department of Thoracic Oncology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
  • Hu C; Department of Thoracic Oncology, Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, China.
  • Su S; Teaching and Research Department of Oncology, Clinical Medical College of Guizhou Medical University, Guiyang, China.
  • Ma Z; Department of Thoracic Oncology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
  • Geng Y; Department of Thoracic Oncology, Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, China.
  • Hu Y; Teaching and Research Department of Oncology, Clinical Medical College of Guizhou Medical University, Guiyang, China.
  • Jin H; Department of Thoracic Oncology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
  • Li H; Department of Thoracic Oncology, Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, China.
  • Lu B; Teaching and Research Department of Oncology, Clinical Medical College of Guizhou Medical University, Guiyang, China.
Cancer Med ; 12(14): 14949-14959, 2023 07.
Article in En | MEDLINE | ID: mdl-37288833
ABSTRACT

BACKGROUND:

EGFR-mutant (EGFR-M) and ALK-positive (ALK-P)are common in malignant pleural effusion (MPE) with metastatic non-small-cell lung cancer (NSCLC) (MPE-NSCLC). The impact of thoracic tumor radiotherapy on survival in such patients remains unclear. We aimed to investigate whether thoracic tumor radiotherapy could improve overall survival (OS) in such patients.

METHODS:

According to whether or not patients accepted thoracic tumor radiotherapy, 148 patients with EGFR-M or ALK-P MPE-NSCLC treated with targeted therapy were classified into two groups DT group without thoracic tumor radiotherapy and DRT group with thoracic tumor radiotherapy. Propensity score matching (PSM) was performed to balance clinical baseline characteristics. Overall survival was analyzed by Kaplan-Meier, compared by log-rank test, and evaluated using Cox proportional hazards model.

RESULTS:

Median survival time (MST) was 25 months versus 17 months in the DRT group and DT group. The OS rates at 1, 2, 3, 5 years in the DRT group and DT group were 75.0%, 52.8%, 26.8%, 11.1% and 64.5%, 28.4%, 9.2%, 1.8%, respectively (χ2 = 12.028, p = 0.001). Compared with DT group, the DRT group still had better survival after PSM (p = 0.007). Before and after PSM, factors associated with better OS through multivariable analysis were that thoracic tumor radiotherapy, radiotherapy, N0-2 , and ALK-TKIs. Grades 4-5 radiation toxicities were not observed in patients; 8 (11.6%) and 7 (10.1%) out of the DRT group suffered from Grade 3 radiation esophagitis and radiation pneumonitis, respectively.

CONCLUSION:

Our results for EGFR-M or ALK-P MPE-NSCLC showed that thoracic tumor radiotherapy may be crucial factor in improving OS with acceptable toxicities. Potential biases should not be neglected Further randomized controlled trials are necessary to confirm this result.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pleural Effusion, Malignant / Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Clinical_trials / Prognostic_studies Limits: Humans Language: En Journal: Cancer Med Year: 2023 Document type: Article Affiliation country: China

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pleural Effusion, Malignant / Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Clinical_trials / Prognostic_studies Limits: Humans Language: En Journal: Cancer Med Year: 2023 Document type: Article Affiliation country: China